Why the study?
LIPCAR is elevated in HFrEF and associated with remodeling and poor prognosis, prompting investigation into its role as a biomarker for early detection of HF post-AMI.
Does circulating LIPCAR level predict the diagnosis of heart failure in patients post-acute myocardial infarction?
Does circulating LIPCAR level predict the diagnosis of heart failure in patients post-acute myocardial infarction?
Circulating LIPCAR levels are significantly elevated in patients who develop heart failure after an acute myocardial infarction, demonstrating high diagnostic accuracy (AUC 0.985) as a potential early biomarker.
Answers are grounded in this paper and cite their sources.
LIPCAR may support post-AMI HF diagnosis; hypothesis-generating and should not yet change practice pending prospective validation.
In heart failure (HF) patients with reduced ejection fraction, LIPCAR, a long noncoding RNA is elevated and is associated with left ventricular remodeling and poor prognosis. We studied the role of LIPCAR in patients with HF post-acute myocardial infarction (AMI) to find biomarkers for early detection of HF. We conducted a study of 127 patients with AMI, of which 59 were patients with HF post-AMI. LIPCAR levels were higher in HF patients post-AMI than patients without HF, and LIPCAR had a high predictive value for diagnosis of HF, which was estimated by receiver operating characteristic curves (AUC: 0.985). The results indicate that LIPCAR may be a marker of early HF after AMI.
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: